Overview#

NRC Health has announced its Q1 2026 earnings, revealing a return to revenue growth after several years of decline. The company reported earnings per share (EPS) of $0.21, an increase from $0.16 in the previous quarter. Revenue reached $34.8 million, reflecting a 4% year-over-year growth. However, the stock price fell slightly by 1.23% in aftermarket trading, closing at $16.9.

Key Highlights#

NRC Health's performance in Q1 2026 marks a significant turnaround, with a 4% revenue increase compared to the same quarter last year. The Total Recurring Contract Value (TRCV) reached a record high of $152.1 million, indicating strong demand for the company's services. Notably, NRC Health signed its largest deal to date, which is expected to enhance profit margins in the future.

Financial Performance#

  • Revenue: $34.8 million, a 4% increase year-over-year.
  • Earnings per Share: $0.21, up from $0.16 in Q4 2025.
  • Adjusted EBITDA: $9.4 million, representing a 27% margin.
  • Free Cash Flow: $5.3 million, nearly a 50% increase compared to the previous year.

Market Reaction#

After the earnings announcement, NRC Health's stock price declined by 1.23%, closing at $16.9. This drop is modest considering the company has achieved a 60.7% return over the past year. The price-to-earnings ratio stands at 33.56, suggesting a premium valuation. Despite the dip, some analysts believe the stock may still be undervalued, as it approaches its 52-week low, reflecting cautious investor sentiment.

Future Outlook#

Looking ahead, NRC Health expects flat adjusted EBITDA margins in Q2 2026 due to costs related to its landmark deal. However, margins are projected to improve in Q3 2026 as revenue begins to reflect the recent growth in TRCV. CEO Michael Hays emphasized the importance of this revenue growth, while CFO John Doe expressed confidence in managing expenses and enhancing margins as new agreements take effect.

Risks and Challenges#

The company faces potential risks, including rising corporate expenses that could pressure margins and seasonal revenue fluctuations that may affect quarterly performance. The stock's proximity to its 52-week low suggests it may experience volatility in the near term.